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Abstract
Introduction: Pathologic accumulation and activation of 
mast cells and eosinophils are implicated in allergic and in-
flammatory diseases. Sialic acid-binding immunoglobulin-
like lectin (Siglec)-8 is an inhibitory receptor selectively ex-
pressed on mast cells, eosinophils and, at a lower extent, ba-
sophils. When engaged with an antibody, Siglec-8 can 
induce apoptosis of activated eosinophils and inhibit mast 
cell activation. AK002 is a humanized, non-fucosylated IgG1 
anti-Siglec-8 antibody undergoing clinical investigation for 
treatment of allergic, inflammatory, and proliferative diseas-
es. Here we examine the human tissue selectivity of AK002 
and evaluate the in vitro, ex vivo, and in vivo activity of AK002 
on eosinophils and mast cells. Methods: The affinity of AK002 
for Siglec-8 and CD16 was determined by biolayer interfer-
ometry. Ex vivo activity of AK002 on human eosinophils from 
blood and dissociated human tissue was tested in apoptosis 
and antibody-dependent cell-mediated cytotoxicity (ADCC) 
assays. The in vivo activity of a murine precursor of AK002 
(mAK002) was tested in a passive systemic anaphylaxis (PSA) 
humanized mouse model. Results: AK002 bound selectively 
to mast cells, eosinophils and, at a lower level, to basophils 
in human blood and tissue and not to other cell types exam-
ined. AK002 induced apoptosis of interleukin-5-activated 
blood eosinophils and demonstrated potent ADCC activity 
against blood eosinophils in the presence of natural killer 
cells. AK002 also significantly reduced eosinophils in dissoci-
ated human lung tissue. Furthermore, mAK002 prevented 
PSA in humanized mice through mast cell inhibition. Conclu-
sion: AK002 selectively evokes potent apoptotic and ADCC 
activity against eosinophils and prevents systemic anaphy-
laxis through mast cell inhibition. © 2019 The Author(s) 
Published by S. Karger AG, Basel
Edited by: H.-U. Simon, Bern.
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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Introduction
Accumulation and inappropriate activation of mast 
cells and eosinophils are associated with pathogenesis of 
many allergic and inflammatory conditions. In addition 
to being primary effector cells in allergic responses, mast 
cells and eosinophils typically co-localize at sites of chron-
ic allergic inflammation, communicating via soluble me-
diators and physical contact to sustain inflammation and 
exacerbate disease. Despite their prominent role in the 
pathogenesis of multiple inflammatory diseases, to date, 
no single therapeutic approach directly targets both cell 
types.
Sialic acid-binding immunoglobulin-like lectin (Si-
glec)-8 is an inhibitory receptor of the CD33-related sub-
family of Siglecs and found only in humans and some 
primates [1–3]. Siglec-8 expression is restricted to ma-
ture mast cells, eosinophils and, to a much lower extent, 
basophils [2]. When engaged with an anti-Siglec-8 
monoclonal antibody (mAb), Siglec-8 induces apoptosis 
of cytokine-activated eosinophils and inhibits mast cell 
activation [4, 5]. Activation of eosinophils with pro-in-
flammatory cytokines sensitizes eosinophils to apopto-
sis-inducing effects of anti-Siglec-8 antibodies. Several 
inflammatory cytokines enhance sensitivity to anti-Si-
glec-8-mediated killing, including interleukin (IL)-5, 
granulocyte-macrophage colony stimulating factor 
(GM-CSF), and IL-33 [5–8]. In contrast to their effect on 
eosinophils, anti-Siglec-8 mAbs do not induce apoptosis 
in resting or activated mast cells [4]. Instead, they inhib-
it IgE-mediated degranulation and de novo synthesis of 
prostaglandin D2 in vitro [4].
Here we characterize the selectivity of Siglec-8 on hu-
man primary tissues and the mechanism of action of 
AK002, a novel humanized anti-Siglec-8 IgG1 antibody 
under therapeutic investigation in allergic and inflamma-
tory diseases.
Materials and Methods
Human Siglec Cross-Reactivity Enzyme-Linked 
Immunosorbent Assay
Recombinant human Siglecs 1–3, 5–7, 9–11, and 14 proteins 
were purchased from R&D Systems, Siglec-4 was purchased from 
Sino Biological, Siglec-12 was purchased from Origene, and Si-
glec-8 was produced at Allakos Inc. MaxisorpTM (Thermo Fisher 
Scientific) immunoassay microplates were coated with human Si-
glec proteins (0.1 mL of 0.2 μg/mL for each protein diluted in Tris-
buffered saline [50 mM Tris-Cl, pH 7.6, 150 mM NaCl]). The en-
zyme-linked immunosorbent assay (ELISA) plates were sealed and 
incubated overnight at 4  ° C. The following day, plates were washed 
4 times with 0.3 mL per well of phosphate-buffered saline (PBS) 
with Tween-20 (PBST; PBS [137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4]) plus 0.1% v/v Tween-20. The plates were blocked with 
0.3 mL of blocking buffer (2% bovine serum albumin (BSA) in 
PBST) and placed on a shaker set to 650 revolutions per minute 
(RPM) for 1 h at room temperature. The blocking buffer was re-
moved by washing and 0.1 mL of AK002 (2 μg/mL; Allakos, Inc.); 
1 μg/mL mouse anti-DYKDDDDK epitope (DDK) was added to 
wells that contained DDK-tagged Siglec proteins in coating con-
trol wells. All other wells received the equivalent volume of block-
ing buffer. The plates were then incubated at room temperature for 
2 h with shaking. The plates were then washed and secondary an-
tibody or horseradish peroxidase (HRP) conjugates were added as 
follows: 0.5 μg/mL of goat antihuman F(ab’)2-HRP or donkey an-
ti-mouse (heavy and light chain [H+L])-HRP were added to 
AK002 antibody wells; 0.1 mL of 0.5 μg/mL donkey anti-human 
IgG (H+L)-HRP was added for Fc-tagged Siglecs; 0.5 μg/mL of 
donkey anti-mouse IgG (H+L)-HRP polyclonal antibody was add-
ed for mouse anti-DDK mAb wells; or 2 μg/mL of mouse anti-His 
HRP mAb was added for 6xHis-tagged Siglecs. The plates were 
then incubated for 1 h at room temperature with shaking. Plates 
were then washed with PBST and 0.1 mL of tetramethylbenzidine 
substrate (Sigma-Aldrich) was added to each well. After 2 min, the 
reaction was terminated by adding 0.1 mL 1 M sulfuric acid. The 
converted substrate was detected in a spectrophotometer at 450 
nm.
Blood and Tissue Samples
Human blood was processed by lysing red blood cells with am-
monium-chloride-potassium buffer and washed in PBS (Thermo 
Fisher Scientific) to obtain peripheral blood leukocytes (PBL). PBL 
were resuspended in RPMI 1640 medium + 10% fetal bovine se-
rum (FBS), (Thermo Fisher Scientific). Fresh human lung and skin 
tissues were procured and provided by the NCI Cooperative Hu-
man Tissue Network from subjects with no previous history of 
chronic lung disease. Other investigators may have received spec-
imens from the same tissue specimens. Human tissue was enzy-
matically and mechanically dissociated using the gentleMACsTM 
Dissociator (Miltenyi Biotec), according to manufacturer’s proto-
col. Tissue was minced into 2 mm pieces and incubated at 37  ° C 
for 1 h in digestion solution containing proprietary enzymes. Be-
fore, during, and after incubation, tissue was mechanically disrupt-
ed and run through a 70-micron filter to obtain single cells. Cells 
were then treated with RBC lysing buffer, washed in PBS, and re-
suspended in RPMI 1640 + 10% Low IgG FBS. Immediately after 
digestion, cell viability was examined using flow cytometry. Only 
single-cell suspensions from dissociated tissue that had at least 
70% viability were used in subsequent experiments.
Flow Cytometry Analysis in Blood and Tissue
Approximately 0.1–0.5 × 106 cells/well were incubated in 96-
well plates with Human Fc BlockTM (BD Biosciences) for 10 min at 
4  ° C followed by staining with conjugated antibodies for 10 min at 
4  ° C. Cells were then washed with FACS buffer (0.1% BSA in PBS), 
resuspended in fixative (1% paraformaldehyde in PBS), and ana-
lyzed on a NovoCyte flow cytometer (Acea Biosciences). A mini-
mum 100,000 events/sample were collected for each experiment. 
Antibodies and gating strategies are further described in the online 
supplementary Materials (for all online suppl. material, see www.
karger.com/doi/10.1159/000501637).
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Siglec-8 Receptor Density Quantification
Siglec-8 receptor density was determined by incubating PBL 
purified from healthy blood with a saturating concentration of Al-
exa Fluor® 647-conjugated Siglec-8 mAb (Allakos, Inc.) for 10 min 
on ice. PBL were co-stained with FACS antibodies against indi-
vidual cell types, and populations were identified by staining and 
scatter as described in the supplement. Quantum Alexa Fluor® 647 
molecules of equivalent soluble fluorochrome (MESF) calibration 
standards (Bangs Laboratories, Inc.) were analyzed concurrently 
to allow conversion of median fluorescence intensity measure-
ments to MESF units, according to manufacturer’s protocol (Bangs 
Laboratories, Inc.). Background fluorescence was removed by sub-
tracting the fluorescence minus one MESF values. MESF values 
were divided by the fluorophore: protein ratio (as determined by 
mass spectrometry) to convert to antibody binding capacity or re-
ceptor density.
Eosinophil ex vivo Depletion Assays in Human PBL or Tissue
Human PBL was prepared by removing red blood cells as de-
scribed above. Human lung tissue was procured and dissociated 
into single cells as described above. Cells were suspended in RPMI 
1640 medium containing 10% low IgG FBS and 1× Penicillin 
Streptomycin (Thermo Fisher Scientific). Approximately 0.1– 
0.5 × 106 cells were plated/well in 96-well U-bottom plates with 
either 1 µg/mL AK002 or non-fucosylated hIgG1 isotype control 
antibodies (Allakos, Inc.) followed by overnight incubation at 
37  ° C. After overnight incubation, live eosinophils were identified 
(blood eosinophils: CD45+ 7AAD– CD16– CCR3+; tissue eosino-
phils: CD45+ 7AAD– SSCHi CD16– CCR3+) and quantified by 
flow cytometry. The percent of eosinophils remaining was calcu-
lated by normalizing the percent of CD45+ eosinophils in the iso-
type control treated wells to 100%.
Monovalent and Bivalent Affinity Determination 
Binding affinities of fragment antigen-binding (Fabs) and IgG 
for Siglec-8 extracellular domain (ECD) were measured by bio-
layer interferometry using a FortéBio Octet Red 384 instrument at 
25  ° C at 1,000 rpm in 1× kinetics buffer (HEPES-buffered saline; 
GE Healthcare) in ultrapure water, with added stabilizer (For-
téBio). Fabs or IgGs were diluted from 12.5 to 0.78 nM in assay 
buffer in a 2-fold dilution series. Siglec-8 ECD polyethylene glycol 
biotinylated protein (Allakos, Inc., San Carlos, CA, USA) was im-
mobilized on streptavidin sensors at 100 nM in 1× kinetics buffer 
for 3 min until a sensor change of approximately 1.8 nm was 
achieved. The association phase was 2 min followed by a 10-min 
dissociation phase. An empty reference cell sensor was used as a 
blank control, and affinities analyzed using FortéBio analysis soft-
ware with 1: 1 global fit parameters. See online supplementary Ma-
terials for details.
Apoptosis Assay
Human eosinophils were purified (see online suppl. Material) 
and cultured overnight in 50 ng/mL of IL-5. Cells were then seed-
ed in 96-well flat-bottom tissue culture plates at 50,000 eosino-
phils/well. AK002, AK002-G4, non-fucosylated hIgG1 isotype 
control, or hIgG4 isotype control antibodies (Allakos, Inc.) were 
added in a 10-fold dilution series between 10 μg/mL and 1 pg/mL 
in the presence of 50 ng/mL IL-5. Cells were cultured overnight at 
37   ° C in 5% CO2. Following overnight incubation, cells were 
stained with 7AAD and Annexin V-PE (BD Biosciences) for 30 
min at room temperature in the dark. The labeled eosinophils were 
analyzed by flow cytometry, and percentage of Annexin V-positive 
eosinophils was determined.
Antibody-Dependent Cell-Mediated Cytotoxicity Assay
Human eosinophils were purified (see online suppl. Material) 
and seeded in 96-well U-bottom tissue culture plates at 50,000 eo-
sinophils/well. Purified human natural killer (NK) cells (AllCells) 
were washed with culture medium and added at 450,000 cells/well 
(effector: target cell ratio 9: 1). Plates were incubated for 4 h at 37  ° C 
in 5% CO2 for the induction of antibody-dependent cell-mediated 
cytotoxicity (ADCC) activity. After incubation, the plates were 
centrifuged at 300 g for 2 min, and 50 μL of supernatant was re-
moved from each well for assay of lactate dehydrogenase to deter-
mine potential ADCC activity of the treatment antibodies. Lactate 
dehydrogenase assays were performed as follows: to each superna-
tant, 50 µL CytoTox96 Assay reagent (Promega, Madison, WI, 
USA) was added and incubated for 30 min at room temperature. 
At the end of color development, 50 µL Stop Solution (Thermo 
Fisher Scientific) was added, and the absorbance (optical density 
[OD] 495 nm) was determined. As a control, 20 µL of 10× cell lysis 
buffer (Promega) was added to an aliquot of cells to determine 
maximal lysis. Percent cell death was calculated for each antibody 
in replicate wells by dividing each sample’s OD value by the OD 
value for 100% eosinophil lysis.
Passive Systemic Anaphylaxis Model
Passive systemic anaphylaxis (PSA) was induced using chime-
ric human (ch) IgE mAb as previously described [9]. NSG-SGM3 
BLT mice (see online suppl. Material) were intravenously dosed 
with either 100 μg mouse IgG1 isotype control mAb (Eureka Ther-
apeutics) or the mouse precursor of AK002 (mAK002; Allakos, 
Inc.). Then, 24 h later NSG-SGM3 BLT mice were primed with 
intravenous injection of 1.6 µg of ch IgE-anti-hapten 4-hydroxy-3 
nitrophenacetyl (NP) antibody (Biosearch Technologies) in 200 
µL and anaphylaxis was initiated 24 h later by intravenous injec-
tion of 500 µg of NP-conjugated BSA in 100 µL of PBS. Anaphy-
laxis was defined as a significant decrease in core body temperature 
and observable symptom scores as described and adapted from 
Ganeshan et al. [10] and Li et al. [11]. Two blinded investigators 
assessed symptom scores.
Results
AK002 Binds Specifically to Siglec-8 and Interacts 
with CD16a
AK002 is a humanized non-fucosylated IgG1 antibody 
with the binding specificity of the mouse anti-Siglec-8 
mAb 2E2 [5–7]. Using a panel of human Siglec proteins, 
AK002 bound specifically to the ECD of Siglec-8 and did 
not show detectable cross-reactivity with other recombi-
nant Siglec ECDs by ELISA (Fig. 1a). Kinetics for AK002 
binding to recombinant Siglec-8 ECD were analyzed by 
biolayer interferometry. The binding affinity of a mon-
ovalent AK002 Fab was determined to be 464 pM, and the 
bivalent avidity of AK002 was < 1 pM (Fig. 1b, c). 
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To determine whether AK002 has high affinity for 
CD16 (FcγRIII), as described for other non-fucosylated 
IgG1 antibodies [12, 13], CD16a and CD16b binding as-
says were performed by biolayer interferometry. The Fc 
region of AK002 had minimal interaction with immobi-
lized CD16b, whereas the affinity of the Fc region of 
AK002 for immobilized CD16a (158V variant) was de-
termined to be 9.88 nM (online suppl. Fig. S1a, b), con-
sistent with previous reports of the affinity of non-fu-
cosylated IgG1 antibodies for CD16a [12–14]. In con-
trast, a human IgG4 version of AK002 (AK002-G4), with 
identical variable regions to AK002 and similar bivalent 
avidity to Siglec-8 ECD (online suppl. Fig. S1c), did not 
have detectable affinity for CD16a (online suppl. Fig. 
S1d). 
Next, we studied binding of AK002 to CD16a and Si-
glec-8 on human NK cells, T cells, eosinophils, and oth-
er immune cells from peripheral blood (online suppl. 
Fig. S1e). Both AK002 and AK002-G4 bound similarly 
to eosinophils, whereas only AK002 bound to NK cells 
(Fig.  1d). In contrast, no binding was observed on T 
cells, neutrophils, monocytes, or B cells, and very mini-
mal binding was observed on basophils (Fig. 1d; online 
suppl. Fig. S2a). In human PBL, AK002 showed dose-
dependent binding to eosinophils, whereas binding to 
NK cells was only detectable at higher concentrations, 
consistent with the relative affinities of AK002 for Si-
glec-8 and recombinant CD16a (Fig. 1e). Additionally, 
AK002-F(ab’)2, which lacks an Fc region, bound only to 
eosinophils but not NK cells or T cells (online suppl. Fig. 
S2b). These data demonstrate that AK002 binds with 
high affinity to Siglec-8 in vitro, to Siglec-8 expressed on 
eosinophils, and to NK cells via its Fc region in human 
blood.
Selective Binding of AK002 to Eosinophils in Human 
Peripheral Blood
To evaluate the selectivity of AK002, we used AK002-
G4 instead of AK002 to avoid Fc-mediated binding to 
CD16a-expressing cells. Human peripheral blood was 
analyzed using multi-color flow cytometry to identify im-
mune cell populations that express Siglec-8 (Fig.  2a). 
Consistent with previously published literature using 
murine anti-Siglec-8 mAbs [1, 2], AK002-G4 binding was 
observed only on eosinophils and, at much lower levels, 
on basophils (Fig. 2b, c). AK002-G4 did not bind blood 
neutrophils, monocytes, B cells, T cells, or NK cells 
(Fig. 2b, c; online suppl. Fig. S2c). The robust expression 
of Siglec-8 on eosinophils was further confirmed using a 
commercially available anti-Siglec-8 mAb (online suppl. 
Fig. S2d). Immune cells that stained positive for Siglec-8 
using AK002-G4 (Fig. 2b) were further analyzed by flow 
cytometry to estimate Siglec-8 receptor density using the 
antibody-binding capacity of an anti-Siglec-8 antibody. 
Peripheral blood eosinophils had an average anti-Siglec-8 
binding capacity of ∼18,000 per cell, compared with only 
∼550 per cell for basophils (Fig. 2d).
Selective Binding of AK002 to Eosinophils and Mast 
Cells from Human Lung Tissue
Recruitment of eosinophils from the bloodstream into 
tissue may be associated with altered expression of cell-
surface molecules needed to sustain inflammatory and 
remodeling responses in the local milieu [15]. To investi-
gate whether Siglec-8 expression was altered in tissue, we 
examined the binding of AK002-G4 in cells derived from 
dissociated human lung tissue. Using multicolor flow cy-
tometry, we identified immune cell populations routinely 
found in lung, including eosinophils, mast cells, baso-
phils, neutrophils, lymphocytes, monocytes, and macro-
phages (Fig. 3a). Similar to peripheral blood, AK002-G4 
only bound to eosinophils and mast cells, and much less 
to basophils (Fig. 3b, c). AK002-G4 binding was not de-
tected on other CD45-positive immune cells in the lung 
(Fig. 3b, c; online suppl. Fig. S2d, e). The robust expres-
sion of Siglec-8 on eosinophils and mast cells was again 
confirmed using a commercially available anti-Siglec-8 
mAb (online suppl. Fig. S3a). In addition, AK002-G4 did 
not bind to CD45-negative cells in human lung tissue 
(Fig. 3d, e; online suppl. Fig. S3b). The Siglec-8-specific 
AK002-G4 binding profile found in human lung tissue 
was also consistent with the binding profile using human 
skin tissue (online suppl. Fig. S3c–e). These data demon-
strate that AK002-G4 binding, and therefore Siglec-8 ex-
pression, is specific to eosinophils, mast cells and, to a 
lower extent, basophils in both human lung and skin tis-
sues. 
Tissue-derived cells that expressed Siglec-8 (Fig. 3b) 
were further analyzed to quantify the receptor density of 
Siglec-8. Lung tissue eosinophils had an average anti-Si-
glec-8 binding capacity of ∼21,500 per cell and mast cells 
had an average binding capacity of ∼22,200 per cell 
(Fig. 3f). As in peripheral blood, lung basophils displayed 
markedly lower expression of Siglec-8 than on eosino-
phils, with an average binding capacity of ∼620 per cell 
(Fig. 3f). These data show that eosinophils from lung tis-
sue have a similar number of Siglec-8 receptors as periph-
eral blood eosinophils, suggesting that Siglec-8 expres-
sion is not significantly altered after migration into lung 
tissue.
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Fig. 1. AK002 is a non-fucosylated, humanized antibody that is 
specific for Siglec-8 and interacts with CD16a on NK cells. a AK002 
specificity and cross-reactivity was examined using a recombinant 
human Siglec cross-reactivity ELISA. Recombinant Siglecs were 
coated on the plate overnight at 0.2 µg/mL and AK002 was added 
at 2 µg/mL for 2 h. The binding kinetics of (b) monovalent AK002 
Fabs or (c) full-length IgG AK002 (two-fold dilutions from 12.5 to 
0.8 nM) to the Siglec-8 ECD antigen was measured using biolayer 
interferometry. The following kinetic parameters were determined 
for the Fab and full-length IgG, respectively: kon = 1.04 × 106 1/Ms, 
koff = 4.82 × 10–4 1/s, Kd = 464 pM and kon = 1.86 × 106 1/Ms, since 
no significant dissociation was observed for the measured time of 
600 s Kd was assigned to < 1 pM. d Binding of 50 nM AK002-G4 
(light blue) and AK002 (dark blue) to eosinophils, NK cells, and T 
cells gated as shown in (c) in human peripheral blood by flow cy-
tometry. e Titration of AK002 binding in human peripheral blood 
to eosinophils, NK cells, and T cells gated as shown in panel C by 
flow cytometry. Siglec, sialic acid-binding immunoglobulin-like 
lectin; NK, natural killer; MFI, median fluorescence intensity; 
FMO, fluorescence minus one.
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AK002 Induces Apoptosis and Has Potent ADCC 
Activity on Human Eosinophils in vitro
Anti-Siglec-8 mAbs have been shown previously to di-
rectly induce apoptosis of isolated human eosinophils, an 
effect that is enhanced by the activation of eosinophils 
with IL-5 and other cytokines [4, 5, 7]. Consistent with 
these reports, AK002 directly induced dose-dependent 
apoptosis of IL-5-activated eosinophils purified from hu-
man blood (Fig. 4a; online suppl. Fig. S4a). To determine 
ADCC-specific cell killing by AK002, human blood eo-
sinophils were co-cultured with NK cells in the absence 
of eosinophil-activating cytokines to suppress AK002-in-
duced apoptosis. In the presence of purified NK effector 
cells, AK002 demonstrated rapid ADCC activity against 
blood eosinophils (Fig. 4b). In contrast, when AK002-G4 
was similarly tested in the presence of NK cells, no ADCC 
activity was observed (online suppl. Fig. S4b). Next, hu-
man PBL was used to examine the ADCC activity of 
AK002. Although IL-5 was not included in these cultures, 
AK002 potently depleted eosinophils in PBL preparations 
from healthy donors in a dose-dependent manner 
(EC50 = 1.9 ng/mL), compared to isotype or AK002-G4 
controls (Fig.  4c; online suppl. Fig. S4c, d), an activity 
consistent with ADCC-mediated killing. No reduction 
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Fig. 2. AK002-G4 selectively binds to eosinophils and basophils in 
human peripheral blood. a Flow cytometry gating strategy used to 
identify immune cell subtypes among human PBL. b AK002-G4 
binding plotted as ΔMFI on immune cells identified using gating 
strategy in a (mean ± SD of 4 donors). c Representative histograms 
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of peripheral blood eosinophils (median 18,029 ± 6,133) and ba-
sophils (median 552 ± 292) determined by quantitative cytometry 
(individual donors are plotted ± SD). ΔMFI was determined by 
subtracting the MFI for a FMO control sample from the MFI for 
cells stained with the conjugated antibody. ΔMFI values that were 
negative after subtracting the FMO were given a value of zero. 
ABC, antibody binding capacity; MFI, median fluorescence inten-
sity; FMO, fluorescence minus one; NK, natural killer.
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the MFI for cells stained with the conjugated antibody. ΔMFI val-
ues that were negative after subtracting the FMO were given a val-
ue of zero. MFI, median fluorescence intensity; FMO, fluorescence 
minus one; NK, natural killer; ABC, antibody binding capacity.
Youngblood et al.Int Arch Allergy Immunol 2019;180:91–10298
DOI: 10.1159/000501637
was seen in the numbers of other immune cells found in 
PBL preparations (online suppl. Fig. S4e), consistent with 
the selective expression of Siglec-8. These data demon-
strate that AK002 has dual activity on human eosinophils: 
direct induction of apoptosis of IL-5-activated eosino-
phils via Siglec-8 and induction of potent ADCC activity 
against eosinophils in the presence of NK cells.
AK002 Reduces Eosinophil Numbers in ex vivo 
Human Tissue
To begin evaluating the activity of AK002 against tis-
sue eosinophils, we phenotyped eosinophils by flow cy-
tometry to compare surface marker expression between 
blood and tissue eosinophils. Two cell-surface markers, 
CD62L and IL-5 receptor were highly expressed on pe-
ripheral blood eosinophils but were significantly down-
regulated on eosinophils from human lung tissue 
(Fig. 5a, b) [16, 17]. In contrast, Siglec-8 expression was 
comparable on blood and tissue eosinophils (Fig. 5a, b). 
AK002 significantly reduced eosinophils in ex vivo dis-
sociated lung tissue suspensions from multiple donors 
compared to an isotype control antibody in the absence 
of exogenous cytokine (Fig.  5c, d), indicating that 
AK002 can reduce both blood and tissue eosinophils. 
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eosinophils incubated overnight with AK002 (blue) or isotype 
control antibody (gray) followed by apoptosis detection using An-
nexin V-PE and 7AAD (mean ± SD of 4 biological replicates). 
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Unlike the activity against eosinophils, AK002 did not 
decrease mast cell numbers in ex vivo dissociated tissue 
suspensions, consistent with the non-apoptosis-induc-
ing activity of Siglec-8 on mast cells (online suppl. Fig. 
S4f) [4].
mAK002 Inhibits PSA in Humanized Mice
Crosslinking of Siglec-8 on human mast cells previ-
ously has been shown to inhibit IgE-mediated mast cell 
activation in vitro [4, 18]. To examine the in vivo mast cell 
inhibitory potential of AK002, we tested a mouse precur-
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Fig. 5. AK002 reduces human tissue eosinophils ex vivo. a Surface 
expression of CD62L, IL-5Rα and Siglec-8 plotted as ΔMFI on 
blood (black) and lung tissue (gray) eosinophils (mean ± SD of 4 
donors). b Representative histograms of surface expression of IL-
5Rα (red), Siglec-8 (blue) or fluorescence minus one negative con-
trol (gray) on blood and lung tissue eosinophils. c, d Dissociated 
human tissue was incubated overnight with 1 μg/mL isotype con-
trol (gray) or AK002 (blue). Eosinophils were counted by flow cy-
tometry and plotted as the (c) percent eosinophils remaining or as 
(d) absolute eosinophil counts. The percent eosinophils remaining 
was calculated by normalizing to the percent of CD45+ eosinophils 
in the isotype control-treated wells to 100% (mean ± SD of 4 do-
nors). * p < 0.05; ** p < 0.01. MFI, median fluorescence intensity; 
IL5Rα, interleukin-5 receptor α; Siglec, sialic acid-binding immu-
noglobulin-like lectin.
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sor of AK002 (mAK002), using a humanized strain of 
mice (NSG-SCF/GM-CSF/IL3 (NSG-SGM3) engrafted 
with human thymus, liver, and HSC [BLT]), which pro-
duces mature, Siglec-8-expressing, human mast cell pop-
ulations and can generate a PSA response [9]. Siglec-8 
expression is restricted to mature mast cells in these mice 
[9]. As expected, mAK002 has the same binding affinity 
to Siglec-8 ECD and specificity in human blood as AK002 
(online suppl. Fig. S5a, b). PSA was induced using ch IgE-
anti-NP and NP-BSA as antigen (Fig. 6a) [9]. NSG-SGM3 
BLT mice sensitized with chIgE-anti-NP and challenged 
with NP-BSA, but not PBS, demonstrated systemic ana-
phylaxis as characterized by reduction in rectal tempera-
ture and elevated clinical symptom scores (Fig.  6b, c). 
mAK002, administered 24-h before IgE sensitization, 
completely prevented PSA as shown by a lack of change 
in rectal temperature and symptom scores in treated mice 
(Fig. 6b, c). These data demonstrate that mAK002 admin-
istration significantly inhibits IgE-mediated mast cell ac-
tivation in a model of systemic anaphylaxis.
Discussion/Conclusion
Eosinophils and mast cells play pivotal roles in the 
pathogenesis of many allergic and inflammatory diseases. 
They can initiate and maintain allergic and inflammatory 
responses and serve as the primary effector cells leading 
to both acute tissue responses and long-term tissue dam-
age [19]. Siglec-8 is an attractive therapeutic target be-
cause of its selective expression and inhibitory activity on 
eosinophils and mast cells. Here we characterize AK002, 
a novel humanized antibody to Siglec-8 with multiple 
modes of activity against eosinophils and mast cells. 
We show that Siglec-8 is expressed at high levels on the 
surface of eosinophils and mast cells and not on other 
cells in blood or tissues. Receptor quantification indicat-
ed that blood and tissue eosinophils expressed similar lev-
els of Siglec-8 (18,000–21,500), levels comparable to those 
on lung mast cells (22,000). Basophils showed much low-
er levels of Siglec-8 expression (∼600) in both peripheral 
blood and dissociated lung tissue. The high Siglec-8 ex-
pression on blood and tissue eosinophils is consistent 
with recently reported levels of Siglec-8 expression on eo-
sinophils from peripheral blood and bronchoalveolar la-
vage fluid after segmental allergen challenge in subjects 
with allergic asthma [20]. This is in contrast to the expres-
sion of the IL-5 receptor on eosinophils, which is down-
regulated upon migration from the bloodstream into tis-
sues. Siglec-8 therefore provides an attractive opportu-
nity for targeting both mast cells and eosinophils directly 
within tissues as well as eosinophils in peripheral blood.
AK002 bound selectively to Siglec-8 with high affinity 
and showed no detectable binding to other Siglecs by ELI-
SA. By flow cytometry, AK002 bound only to eosinophils 
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Fig. 6. mAK002 inhibits IgE-mediated PSA in humanized mice. 
a Experimental design of PSA in NSG-SGM3-BLT humanized mice. 
NSG-SGM3 BLT mice were treated with either 100 μg of isotype con-
trol antibody (gray) or mAK002 (blue). The next day, the mice were 
systemically sensitized with chIgE-anti-NP antibody and systemi-
cally challenged 24 h later with BSA-NP (solid line) or PBS (dashed 
line). Systemic anaphylaxis was measured by monitoring the rectal 
body temperature (b, c) observable clinical symptom scores as de-
scribed in methods (mean ± SD of 2 experiments; n = 5–10 mice/
group). * p < 0.05. BSA, bovine serum albumin; chIgE, chimeric hu-
man IgE; NP, nitrophenacetyl; PBS, phosphate-buffered saline.
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(and modestly to basophils) in peripheral blood, and to eo-
sinophils and mast cells (and modestly to basophils) in dis-
sociated lung and skin tissues, showing no detectable bind-
ing to other hematopoietic or non-hematopoietic cells.
Previous studies have shown that engagement with an 
anti-Siglec-8 antibody induces apoptosis of cytokine-
primed eosinophils mediated by β2-integrin-dependent 
adhesion and generation of reactive oxygen species [5, 6, 
20]. Multiple cytokines have been shown to enhance the 
sensitivity of eosinophils to Siglec-8-induced apoptosis 
including IL-5, IL-33, GM-CSF [5–8]. Consistent with 
these observations, AK002 induced potent dose-depen-
dent apoptosis of purified IL-5-activated eosinophils.
AK002 was generated as a non-fucosylated IgG1 anti-
body to increase its binding affinity to FcγRIIIA, (CD16a) 
and provide enhanced NK cell-mediated ADCC activities 
in peripheral blood. Indeed, AK002 showed rapid induc-
tion of NK cell-mediated ADCC activity against eosino-
phils in vitro and potent and selective depletion of eosino-
phils from PBLs without a requirement for exogenous cy-
tokines, consistent with ADCC-mediated cell depletion. 
The IgG4 form of AK002, which lacks ADCC function, did 
not induce significant depletion of eosinophils in PBL prep-
arations in the absence of exogenous cytokine, further sup-
porting the importance of CD16a-dependent ADCC for the 
activity of AK002 against peripheral blood eosinophils. 
When using dissociated human lung tissues from mul-
tiple donors, AK002 significantly reduced tissue eosinophil 
numbers, but not mast cells ex vivo. The lack of reduction 
of lung tissue mast cells after AK002 is consistent with pre-
vious studies showing that Siglec-8 ligation does not induce 
apoptosis in mast cells [4]. These data suggest that the 
downstream consequences of signaling via Siglec-8 appear 
to differ between eosinophils and mast cells. Siglec-8 anti-
bodies previously have been shown to kill eosinophils iso-
lated from BAL from asthmatic patients by direct induction 
of apoptosis without the need for exogenous cytokines [6]. 
The ability of AK002 to directly induce apoptosis in cyto-
kine-primed eosinophils suggests that this could be the 
mechanism of lung eosinophil depletion. Thus, AK002 
demonstrates 2 modes of killing activity against eosino-
phils: NK-cell mediated ADCC activity in peripheral blood 
and direct induction of apoptosis of tissue eosinophils.
The lack of mast cell depletion by AK002 in human 
lung tissue suggests that ADCC is not highly active in tis-
sue. In support of this, ADCC has been shown to be me-
diated by NK cells of the CD16Hi phenotype which are 
most abundant in the blood [21, 22]. NK cells found in 
tissue are rare, and even when present are thought to have 
a CD16Lo, CD56Hi phenotype with reduced ADCC activ-
ity [21]. These data suggest that ADCC against eosino-
phils mainly occurs in the blood rather than tissue due to 
differences in number and function of local NK cell pop-
ulations. Despite the lack of ADCC-inducing NK cells in 
lung tissue, AK002 significantly depleted tissue eosino-
phils, likely via other mechanisms of anti-eosinophilic ac-
tivity such as apoptosis.
In addition to the depleting activity against eosino-
phils, anti-Siglec-8 antibodies previously have been 
shown to inhibit mast cell activation in vitro [4, 18]. To 
examine if antibody engagement of Siglec-8 can inhibit 
IgE-mediated mast cell activation in vivo, we used a PSA 
mouse model which produces human mast cells that pop-
ulate the peripheral immune system and mucosal tissues 
[11]. Human mast cells in NSG-SGM3 BLT mice are phe-
notypically similar to primary human mast cells, express-
ing Siglec-8, CD117, tryptase, and IgE receptor [9]. These 
mice developed a human IgE-mediated PSA response fol-
lowing systemic challenge with NP-BSA that was com-
pletely prevented by treatment with mAK002. As a result, 
the dual mechanism of action of AK002 against eosino-
phils, along with its inhibition of mast cell activation, rep-
resents a promising approach for the treatment of allergic 
and inflammatory diseases. 
In summary, we report that Siglec-8 is robustly and 
selectively expressed on eosinophils and mast cells in hu-
man blood and tissue. AK002, a humanized non-fucosyl-
ated IgG1 anti-Siglec-8 antibody, selectively binds to hu-
man eosinophils, mast cells and, to a lesser extent, baso-
phils, consistent with the restricted expression of Siglec-8. 
AK002 has potent ADCC and apoptosis-inducing activ-
ity against peripheral blood eosinophils and human tissue 
eosinophils. The antibody also shows inhibitory activity 
against mast cells in vivo. These findings support the 
therapeutic potential of AK002 for the treatment of eo-
sinophil and mast cell-related diseases and, pursuant 
to this, studies are currently underway in mast cell 
and eosinophilic diseases (eosinophilic gastritis and 
gastroenteritis, chronic urticaria, severe allergic conjunc-
tivitis, and indolent systemic mastocytosis; e.g., Clinical-
trials.gov identifiers NCT03496571, NCT03436797, 
NCT03379311, and NCT02808793).
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